Clinical TrialID 5620
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
NCT00707889
Advanced Colorectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 5620
- Evidence Id
- 5620
- Core Evidence Id
- 5620
- Source Clinical Trial Id
- 5601
- Herb2 Clinical Trial Id
- HBCT005601
- Nct Id
- NCT00707889
- Title
- Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study Result
- No
- Study Condition
- Advanced Colorectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: ABT-869|DRUG: bevacizumab|DRUG: oxaliplatin|DRUG: folinic acid|DRUG: fluorouracil|DRUG: ABT-869
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 159
- Outcome Measure
- Progression-free survival, Radiographic evaluation every 2 months, clinial evaluation every 2 weeks
- Sponsor Collaborator
- AbbVie (prior sponsor, Abbott)|Genentech, Inc.
- Funded By
- INDUSTRY
- Location
- Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, 27599-7305, United States|Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, 19107, United States|Site Reference ID/Investigator# 8360, Nashville, Tennessee, 37232-6307, United States|Site Reference ID/Investigator# 18581, Bedford Park, 5042, Australia|Site Reference ID/Investigator# 23443, Herston, 4029, Australia|Site Reference ID/Investigator# 18023, Bonheiden, 2820, Belgium|Site Reference ID/Investigator# 23646, Brussels, 1200, Belgium|Site Reference ID/Investigator# 18026, Leuven, 3000, Belgium|Site Reference ID/Investigator# 18022, Roeselare, 8800, Belgium|Site Reference ID/Investigator# 26662, Jau, 17210-120, Brazil|Site Reference ID/Investigator# 24245, Porto Alegre, 90610-000, Brazil|Site Reference ID/Investigator# 23265, Barrie, L4M 6M2, Canada|Site Reference ID/Investigator# 21083, Edmonton, T6G 1Z2, Canada|Site Reference ID/Investigator# 22465, Ottawa, K1H 8L6, Canada|Site Reference ID/Investigator# 22141, Nachod, 54769, Czech Republic|Site Reference ID/Investigator# 22289, Heraklion, 71110, Greece|Site Reference ID/Investigator# 22286, Thessaloniki, 54007, Greece|Site Reference ID/Investigator# 22287, Thessaloniki, 56403, Greece|Site Reference ID/Investigator# 18281, Seoul, 110-744, Korea, Republic of|Site Reference ID/Investigator# 18283, Seoul, 135-710, Korea, Republic of|Site Reference ID/Investigator# 18282, Seoul, 138-736, Korea, Republic of|Site Reference ID/Investigator# 20281, Wellington South, 6021, New Zealand|Site Reference ID/Investigator# 20141, Olsztyn, 10513, Poland|Site Reference ID/Investigator# 17946, Warsaw, 02-781, Poland|Site Reference ID/Investigator# 38284, Warsaw, 04-125, Poland|Site Reference ID/Investigator# 23908, Aveiro, 3814-501, Portugal|Site Reference ID/Investigator# 22324, Coimbra, 3001-651, Portugal|Site Reference ID/Investigator# 23724, Faro, 8000-386, Portugal|Site Reference ID/Investigator# 23964, Lisbon, 1099-023, Portugal|Site Reference ID/Investigator# 23303, Baia Mare, 430031, Romania|Site Reference ID/Investigator# 23302, Brasov, 500117, Romania|Site Reference ID/Investigator# 17962, Bucharest, 022328, Romania|Site Reference ID/Investigator# 17964, Bucharest, 022328, Romania|Site Reference ID/Investigator# 23304, Bucharest, 050098, Romania|Site Reference ID/Investigator# 17961, Cluj Napoca, 400015, Romania|Site Reference ID/Investigator# 23305, Craiova, 200385, Romania|Site Reference ID/Investigator# 24422, Moscow, 115478, Russian Federation|Site Reference ID/Investigator# 25063, Moscow, 115478, Russian Federation|Site Reference ID/Investigator# 25065, Moscow, 117997, Russian Federation|Site Reference ID/Investigator# 24423, Moscow, 143423, Russian Federation|Site Reference ID/Investigator# 22809, A Coruna, 15006, Spain|Site Reference ID/Investigator# 22807, Barcelona, 08907, Spain|Site Reference ID/Investigator# 22804, Madrid, 28034, Spain|Site Reference ID/Investigator# 22801, Madrid, 28050, Spain|Site Reference ID/Investigator# 22803, Pamplona Navarra, 31008, Spain|Site Reference ID/Investigator# 22800, Santander, 39008, Spain
- Other Id
- M10-300|2007-007081-38
- Start Date
- 2008-10
- Primary Completion Date
- 2012-05
- Completion Date
- 2012-05
- First Posted
- 2008-07-01
- Results First Posted
- Last Update Posted
- 2013-05-15
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT00707889
- Title Cn
- Title En
- Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
- Bilingual Status
- semi_complete